Sound Science Provides Breakthrough Products

HOW MAX INTERNATIONAL DIFFERENT?

Max International is dedicated to improving everyday lives. This commitment can be seen in everything we do, from our superior products to the charity events we organize around the world. This isn’t some newfound mission; it’s been our focus from Day 1.        Thanks to the efforts of medicinal chemist Dr. Herbert T. Nagasawa and other experts in scientific research and development, Max International has developed groundbreaking advances in glutathione enhancing products. Their patented compound RiboCeine has been the subject of over 20 independent peer reviewed studies.

When our founder, Steven Scott, began developing world-class solutions to the ongoing health crises we all face, he started by tapping leading scientists and employees. Our team is committed to safe and effective products that supplement glutathione, the body’s master antioxidant and a vital protector against free radicals. This dedication has earned Max a U.S. patent for RiboCeine™ one of the core components to a variety of our products. We invite you to learn more about our Executive Team, who help guide and drive our initiatives.

Our Science

Max is committed to producing and delivering the best possible glutathione enhancing products in the world. We know how important it is that high quality health and wellness products be based on proven scientific research. Max International is determined to lead the wellness and nutritional industry in delivering quality products based on science and science-based proprietary formulations that support the body in it's production of Glutathione, one of the body's super anti-oxidants. Glutathione and its benefits have been the subject of over 100,000 peer reviewed articles on PubMed.com, double that of even Vitamin C.                                        

We persevered and our experiments finally led to RiboCeine. This was a Eureka moment for me.                                    

Thanks to the efforts of medicinal chemist Dr. Herbert T. Nagasawa and other experts in scientific research and development, Max International has developed groundbreaking advances in glutathione enhancing products. Their patented compound RiboCeine has been the subject of over 20 independent peer reviewed studies.         

Independent Studies on Ribose-Cysteine

 

NOTE: The following links take you away from this page to 3rd party research sites.

1. Saltman A.E.D-Ribose-L-cysteine supplementation enhances wound healing in a rodent model. Am J Surg. 2015, 210, 153-158.

2. Kader, T.; Porteous C.M.; Williams M.J.A.; Gieseg, S.P.; McCormick, S.P.A. Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. Atherosclerosis. 2014, 237, 725-733.

3. Jurkowska, H.; Uchacz, T.; Roberts, J.; Wrobel, M. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation Amino Acids, 2011, 41, 131-139.

4. Heman-Ackah, S.E.; Juhn, S.K.; Huang, T.C.; Wiedmann, T.S. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation Otolaryngology-Head and Neck Surgery, 2010,143, 429-434.

5. Oz, H.S.; Chen, T.S.; Nagasawa, H., Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Translational Research, , 150(2), 122-129., 150(2), 122-129.

6. Lucas Slitt, A.M.; Dominick, P.K.; Roberts, J.C.; Cohen, S.D. Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion. Basic Clin. Pharmacol. Toxicol., 2005, 96 (6), 487-94.

7. Waldren, C.A., Vannais, D.B., Ueno A.M. A role for long-lived radicals (LLR) in radiation-induced mutation and persistent chromosomal instability: counteraction by Ascorbate and RibCys but not DMSO. Mutation Research, 2004, 551-255-265.

8. Lenarczyk, M.; Ueno, A.; Vannais, D.B.; Kraemer, S.; Kronenberg, A.; Roberts, J.C.; Tatsumi, K.; Hei, T.K.; Waldren, C.A. The "Pro-drug" RibCys Decreases the Mutagenicity of High-LET Radiation in Cultured Mammalian Cells.Radiation Research, 2003, 160, 579-583.

9. Wilmore, B.H.; Cassidy, P.B.; Warters, R.L.; Roberts, J.C. Thiazolidine Prodrugs as Protective Agents against y-Radiation-Induced Toxicity and Mutagenesis in V79 Cells. J. Med. Chem., , 44(16), 2661-2666., 44(16), 2661-2666.

10. Lucus, A.M.; Henning G.; Dominick, P.K.; Whiteley, H.E.; Roberts, J.C.; Cohen, S.D. Ribose Cysteine Protects Against Acetaminophen-Induced Hepatic and Renal Toxicity. Toxicologic Pathology, 2000, 28(5), 697-704.

11. Roberts, J.C.; Phaneuf, H.L.; Dominick, P.K.; Wilmore, B.H.; Cassidy, P.B. Biodistribution of [35S] - Cysteine and Cysteine Prodrugs: Potential Impact on Chemoprotection Strategies. J. Labelled Cpd. Radiopharm., 1999all.riboceine.study1.51

12. Roberts, J.C.; Phaneuf, H.L.; Szakacs, J.G.; Zera, R.T.; Lamb, J.G.; Franklin, M.R. Differential Chemoprotection against Acetaminophen-Induced Hepatotoxicity by Latentiated L-Cysteines. Chem. Res. Toxicol., 1998, 11, 1274-1282.

13. Bantseev, V.; Bhardwaj, R.; Rathbun, W.; Nagasawa, H.T.; Trevithick, J.R. Antioxidants and Cataract: (Cataract Induction in Space Environment and Application to Terrestrial Aging Cataract). Biochem. Mol. Bio. Intl., 1997, 42, 1189-1197.

Roberts, J.C.; Koch, K.E.; Detrick, S.R.; Warters, R.L.; Lubec G. 14. Thiazolidine Prodrugs of Cysteamine and Cysteine as Radioprotective Agents. Radiation Research, 1995, 143, 203-213.

15. Carroll, M.P.; Zera, R.T.; Roberts, J.C.; Schlafmann, S.E.; Feeny, D.A.; Johnston, G.R.; West, M.A.; Bubrick, M.P. Efficacy of Radioprotective Agents in Preventing Small and Large Bowel Radiation Injury. Dis. Colon Rectum, 1995, 38(7), 716-722.

16. Roberts, J.C.;Francetic, D.J.; Zera, R.T. Chemoprotection against Cyclophosphamide-Induced Urotoxicity: Comparison of Nine Thiol Protective Agents. AntiCancer Research, 1994, 14, 389-396.

17. Rowe, J.K.; Zera, R.T.; Madoff, R.D.; Fink, A.S.; Roberts, J.C.; Johnston, G.R.; Freeney, D.A.;Young, H.L.; Bubrick, M.P. Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid. Dis. Colon Rectum, 1993, 36(7), 681-687.

18. Roberts, J.C.; Charyulu, R. L.; Zera, R.T.; Nagasawa, H.T. Protection Against Acetaminophen Hepatotoxicity by Ribose-Cysteine (RibCys). Pharmacology & Toxicology, 1992, 70, 281-285.

19. Roberts, J.C.; Francetic, D.J. Mechanisms of Chemoprotection by RibCys, a Thiazolidine Prodrug of L-cysteine. Med. Chem. Res., 1991, 1, 213-219.

20. Roberts, J.C.; Francetic, D.J. Time course for the elevation of glutathione in numerous organs of L1210-bearing CDF1 mice given the L-cysteine prodrug, RibCys. Toxicology Letters, 1991, 59, 245-251.

21. Roberts, J.C.; Francetic, D.J.; Zera, R.T. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity. Cancer Chemotherapy and Pharmacology, 1991, 28, 166-170.

22. Roberts, J.C.; Nagasawa, H.T.; Zera, R.T.; Fricke, R.F.; Goon, D.J. W. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(polyhydroxyalky)-and 2-(Polyacetoxyalky)-Thiazolidine-4(R)-Carboxylic Acids. . Med Chem., 1987, 30, 1891-1896.